What is the preferred first‑line therapy for a patient with stage IV squamous non‑small cell lung cancer and a PD‑L1 tumor proportion score of 5%?

First-Line Therapy for Stage IV Squamous NSCLC with PD-L1 TPS 5%

For a patient with stage IV squamous non-small cell lung cancer and PD-L1 tumor proportion score of 5%, the preferred first-line therapy is pembrolizumab combined with carboplatin plus paclitaxel (or nab-paclitaxel) for 4 cycles, followed by pembrolizumab maintenance. 1, 2

Rationale for Combination Immunotherapy-Chemotherapy

• Pembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel) is a strong recommendation (moderate evidence quality) for squamous NSCLC with PD-L1 TPS 1-49%, which includes your patient's 5% expression level. 1

• The KEYNOTE-407 trial demonstrated that pembrolizumab-chemotherapy combination yielded median overall survival of 15.9 months versus 11.3 months with chemotherapy alone (HR 0.64,95% CI 0.49-0.85, P<0.001), with consistent benefit across all PD-L1 expression levels including low expressors. 3

• In the intermediate PD-L1 range (1-49%), combination immunotherapy plus chemotherapy produces superior overall survival compared with either modality alone, making it preferable to pembrolizumab monotherapy. 2

• Network meta-analysis specifically examining squamous NSCLC with low PD-L1 (1-49%) confirmed that platinum regimen plus pembrolizumab yielded the best overall survival (HR 0.57,95% CI 0.36-0.90, p=0.016) compared to chemotherapy alone. 4

Specific Treatment Regimen

Administer pembrolizumab 200 mg IV every 3 weeks together with:

• Carboplatin AUC 6 plus paclitaxel 200 mg/m² IV every 3 weeks, OR
• Carboplatin AUC 6 plus nab-paclitaxel 100 mg/m² IV on days 1,8,15 every 3 weeks 1, 2

Continue for 4 cycles of combination therapy, then maintain pembrolizumab monotherapy until disease progression or unacceptable toxicity. 2, 3

Alternative First-Line Options (If Pembrolizumab Unavailable or Contraindicated)

• Cemiplimab plus carboplatin plus paclitaxel – provides comparable efficacy to pembrolizumab-based combinations (moderate evidence, weak recommendation). 1, 2

• Nivolumab plus ipilimumab – dual checkpoint inhibition without chemotherapy (moderate evidence, weak recommendation). 1

• Nivolumab plus ipilimumab plus 2 cycles of platinum-based chemotherapy – yields OS HR 0.61 in PD-L1 1-49% subgroup but carries higher immune-related toxicity. 1, 2

• Durvalumab plus tremelimumab plus platinum-based chemotherapy – emerging regimen with demonstrated OS benefit (moderate evidence, weak recommendation). 1

Critical Pre-Treatment Requirements

Performance status: Patient must have ECOG PS 0-1 to receive pembrolizumab-based combination therapy. 1, 2

Molecular testing: Confirm EGFR-negative and ALK-negative status before initiating immunotherapy; patients with driver mutations require targeted therapy instead. 1, 2

Immunotherapy contraindications: Screen for active autoimmune disease requiring systemic immunosuppression, solid organ transplantation, or chronic corticosteroid use >10 mg prednisone-equivalent daily. 2

Baseline imaging: Obtain brain MRI (more sensitive than CT) to evaluate for CNS metastases, which are common in stage IV disease. 1

Common Pitfalls to Avoid

Do NOT use pembrolizumab monotherapy for PD-L1 5%. Despite FDA approval for PD-L1 ≥1%, monotherapy is inferior to combination therapy in the 1-49% range and should be reserved only for patients with contraindications to chemotherapy or those who decline combination treatment. 1, 2, 5

Do NOT delay treatment to pursue single-agent immunotherapy. The evidence-based standard for PD-L1 1-49% is upfront chemo-immunotherapy combination, not sequential therapy. 2

Do NOT use bevacizumab-containing regimens in squamous histology due to increased risk of pulmonary hemorrhage; bevacizumab combinations are appropriate only for non-squamous NSCLC. 1, 6

Monitoring and Response Assessment

• Perform first radiologic assessment at 6-9 weeks after treatment initiation using RECIST v1.1 criteria. 1

• For immunotherapy-treated patients, apply iRECIST or imRECIST criteria to account for potential pseudoprogression (transient radiographic worsening before response). 1

• Continue pembrolizumab maintenance for up to 24 months or until disease progression or unacceptable toxicity. 2

Palliative Care Integration

Refer to interdisciplinary palliative care teams early in the disease course, alongside active cancer treatment. Early palliative care integration improves both survival and quality of life in stage IV NSCLC. 1